Drug Profile
DNL 104
Alternative Names: DNL104; DNLI-A-002Latest Information Update: 27 Mar 2018
Price :
$50
*
At a glance
- Originator Harvard University
- Developer Denali Therapeutics Inc
- Class Neuroprotectants
- Mechanism of Action RIPK1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Neurodegenerative disorders